U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07610135) titled 'Psilocybin Efficacy With or Without Pimavanserin Pretreatment' on May 20.
Brief Summary: Twenty healthy adults (>=21 years old) will be enrolled to evaluate the efficacy of a single oral dose of psilocybin (25 mg) administered with or without pretreatment using oral pimavanserin (34 mg) or placebo. Outcome assessments will occur at 1 week and 1 month following psilocybin administration.
The purpose of this study is to clarify the receptor-level mechanisms underlying psilocybin's effects on mood and well-being, along with the associated neurophysiologic signatures. These mechanisms will be examined using psychometric scales, autonomi...